Hexarelin dosage: the studied doses, and why there's no safe standing protocol

A dosage page for hexarelin has to start with a caveat, because the most honest thing to say is that there is no “correct” dose. Hexarelin is not an approved medicine, so no regulator has signed off on an amount, a frequency, or a duration. What exists instead is a handful of human studies that injected defined quantities to measure growth-hormone release — and a separate body of community lore that borrows from them. Those are not the same thing. For what the molecule actually does and where its evidence stops, read the hexarelin evidence monograph first; this page is about the numbers and why they are slippery.

The doses that were actually studied

The clearest human dosing data comes from a controlled study that gave hexarelin to healthy young volunteers by four different routes to map its GH-releasing activity. The amounts were small and weight-based: 1 and 2 µg/kg intravenously, 1.5 and 3 µg/kg subcutaneously, 20 µg/kg intranasally, and 20–40 mg orally.^[1] The response was dose-dependent — 2 µg/kg IV produced more GH than 1 µg/kg — and a single 1 µg/kg intravenous dose released roughly twice the GH of an equivalent dose of GH-releasing hormone, which is the headline that earned hexarelin its “potent” reputation.^[1] Note the unit: micrograms per kilogram, a fraction of a milligram for most adults — far below the milligram-scale numbers traded in forums.

Subcutaneous injection was efficient, with a bioavailability around 77%, while the oral and intranasal routes were far less so.^[1] But that efficiency was characterized in single-dosetesting. None of it describes a safe standing protocol, because the moment hexarelin is given repeatedly, a different problem appears.

Why “more and longer” backfires: desensitization

Hexarelin’s central dosing trap is tachyphylaxis — the pituitary desensitizes to it. A study tracking growth-hormone status through long-term hexarelin administration found that the brisk GH response seen on the first dose is not sustained at that magnitude over continued treatment.^[2] In plain terms: the very effect being purchased is the one that erodes the longer the drug is used. This is the opposite of how most people think about dosing — the instinct is that if a little works, more or longer will work better. With hexarelin the molecule itself defeats that instinct, and escalating the dose to chase the original response is not a strategy the pharmacology rewards.

The dose comes bundled with cortisol and prolactin

Dose is not only about how much GH you get — it is also about what else rises with it. In a controlled human study of repeated daily subcutaneous hexarelin, the injections raised not just 24-hour GH but also prolactin, ACTH and cortisol.^[3] A separate human comparison confirmed that hexarelin’s endocrine reach is broader than the natural ghrelin ligand, spilling into the adrenal and lactotroph axes.^[4] That spillover is a property of the dose itself: you cannot isolate the GH pulse from the cortisol and prolactin bump. It is also what distinguishes hexarelin from the selective ipamorelin, which was characterized as the first GH secretagogue that raises GH with little effect on cortisol or prolactin.^[5] Chronically nudging cortisol upward is the reverse of what someone reaching for a “recovery” peptide usually intends.

About the dosing ranges you’ll see online

Community protocols typically describe hexarelin in fixed microgram amounts — often around 100 µg per injection, once or a few times daily — rather than the weight-based, single-probe doses the studies actually used.^[1] Treat those numbers as unvalidated extrapolation, not evidence. They were not arrived at through dose-finding trials with safety monitoring; they emerged from forums. And because hexarelin’s GH effect desensitizes, the daily-injection pattern these protocols recommend is exactly the use case the long-term data warns against.^[2] The honest read is that no one has established a safe, durable hexarelin dose, because the kind of study that would do so has not been run.

Reconstitution, if a clinician is involved

Hexarelin is supplied as a lyophilized powder that has to be reconstituted with bacteriostatic water before any of these microgram amounts can be measured, and small errors there change the delivered dose dramatically. The arithmetic — how vial size, the volume of water added, and the target dose convert into units on an insulin syringe — is exactly what our peptide reconstitution calculator is built to handle. We point to it only because getting the math right is a prerequisite for safety, not because it endorses self-dosing an unapproved drug.

The honest bottom line

If you compress hexarelin dosing to what the evidence supports: it was studied at small weight-based amounts — about 1–2 µg/kg IV and 1.5–3 µg/kg SC — as one-off probes of GH release, not as a daily regimen.^[1] Its GH effect desensitizes with continued use, so escalating the dose works against the goal;^[2] the dose also raises cortisol and prolactin, where the selective ipamorelin does not;^[3][5]and the product is unapproved and unregulated. There is no number on this page anyone should run on their own. Any decision about whether — and how much — belongs with a clinician who can monitor the full endocrine picture. To weigh hexarelin against the rest of the field, see the peptide evidence matrix, and for the regulated provider options, our peptide therapy comparison.